Symphony Financial Ltd. Co. Acquires New Position in FibroBiologics, Inc. (NASDAQ:FBLG)

Symphony Financial Ltd. Co. bought a new position in FibroBiologics, Inc. (NASDAQ:FBLG) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 23,772 shares of the company’s stock, valued at approximately $76,000. Symphony Financial Ltd. Co. owned approximately 0.07% of FibroBiologics at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Fund Evaluation Group LLC bought a new stake in shares of FibroBiologics in the second quarter valued at about $5,265,000. Cascade Financial Partners LLC purchased a new stake in shares of FibroBiologics in the 2nd quarter worth approximately $1,572,000. Transform Wealth LLC bought a new position in shares of FibroBiologics during the second quarter valued at approximately $668,000. Bank of New York Mellon Corp purchased a new position in FibroBiologics during the second quarter valued at approximately $342,000. Finally, RMR Wealth Builders bought a new position in FibroBiologics in the second quarter worth approximately $186,000.

FibroBiologics Trading Down 1.7 %

NASDAQ FBLG opened at $2.83 on Thursday. FibroBiologics, Inc. has a 52 week low of $1.08 and a 52 week high of $55.00. The company has a 50 day moving average price of $2.50 and a 200 day moving average price of $5.80.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). As a group, equities analysts forecast that FibroBiologics, Inc. will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on FBLG. Maxim Group initiated coverage on FibroBiologics in a research report on Tuesday, September 24th. They set a “buy” rating and a $12.00 target price on the stock. EF Hutton Acquisition Co. I raised FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.